Company: KROS
Filing Date: 2025-08-06
Form Type: 8-K
Source: 0001664710-25-000071
Chunk: 0

Company: Keros Therapeutics, Inc.
Filing Date: 2025-08-06
Form: 8-K
Item: Item 5.02
Chunk 0
---
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Appointment of Lorena Lerner as Chief Scientific Officer

On August 6, 2025, Keros Therapeutics, Inc. (the “ Company”) announced that Lorena Lerner, Ph. D., has been appointed to serve as the Company’s Chief Scientific Officer, effective as of August 6, 2025.

Dr. Lerner, age 54, has served as the Company's Senior Vice President, Research since January 2024. Prior to that, Dr. Lerner served as the Company's Vice President, Research beginning in May 2022. From September 2017 to May 2022, Dr. Lerner held multiple positions of increasing responsibility at Oncorus, Inc., including Senior Director, Molecular Biology from September 2017 to December 2018, Vice President, Molecular Biology from January 2019 to November 2021 and Vice President, Research from December 2021 to May 2022. Prior to Oncorus, Inc., Dr. Lerner worked at Quiet Therapeutics from 2016 to 2017, at Scholar Rock Holding Corporation from 2015 to 2016 and at AVEO Pharmaceuticals, Inc. from 2003 to 2015. Dr. Lerner received an M. S. in Molecular Biology and a Ph. D. in Biochemistry from the University of Buenos Aires. She completed her postdoctoral work at The Rockefeller University.

In connection with Dr. Lerner’s employment, the Company entered into an employment agreement, dated August 6, 2025 (the “ Lerner Employment Agreement”), which sets forth certain terms of Dr. Lerner’s employment, effective as of August 6, 2025 (the “ Start Date”).

Pursuant to the Lerner Employment Agreement, Dr. Lerner serves as the Company’s Chief Scientific Officer as of the Start Date. The employment of Dr. Lerner is “at will” and the Lerner Employment Agreement continues until terminated by either party.

Pursuant to the terms of the Lerner Employment Agreement, Dr. Lerner is entitled to an initial annual base salary of $425,000 and an annual discretionary bonus with a target amount equal to 40% of her annual base salary.

Dr. Lerner is eligible to participate in the employee benefit plans generally available to the Company’s employees, and is subject